Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radioactive implant targets pancreatic tumors from the inside

NCT ID NCT07155850

Disease control Sponsor: BetaGlue Therapeutics SpA Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tests a new device called YntraDose™ that delivers a single dose of radiation directly into pancreatic tumors that cannot be removed by surgery. Ten participants will receive the implant along with standard chemotherapy. The main goals are to see if the procedure is safe and feasible, and to measure its impact on tumor response and quality of life over three months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Y-90 microspheres (radioactive implant) delivered via YntraDose™ device
What this could lead to
If it works, this could offer a new way to treat inoperable pancreatic cancer by delivering radiation directly into the tumor, potentially improving tumor control and quality of life.
What could go wrong
This is a very early, small study (10 people) focused on safety and feasibility. It may not show clear benefit, and there are risks from the procedure and radiation, including possible damage to nearby organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria (Main): * Histologically or cytologically proven Pancreatic Adenocarcinoma. * Stage of disease defined as unresectable Locally Advanced Pancreatic Cancer. * No prior radiotherapy for pancreatic cancer. * Target tumour with a minimum diameter of 2.6 cm and a volume of from 9 to 34 ml. * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. * Patient has acceptable hematological parameters including white and red blood counts, liver and renal function that makes them suitable to receive SoC chemotherapy as per local clinical practice. * Life expectancy of ≥6 months at screening. Exclusion Criteria (Main): * Evidence of distant metastases based on the restaging process after two months of induction chemotherapy identified using CT/MRI/18 FDG PET assessment. * Evidence of switch from unresectable status to resectable status of disease after two months of induction chemotherapy. * More than one primary lesion, if one of the primary lesions is not a good candidate for debulking with YntraDose™, due to clinical reasons and/or decision made by the local MDTB. * ECOG is higher than 1. * History of malignancy in the last 3 years. * Blood clotting disorders (INR \> 1.5, PLT \< 50,000/µl - risk of bleeding during organ puncture). * Active systemic or local infection (e.g. peritonitis, abscess). * Severe organ failure (e.g. end-stage liver, kidney, heart failure). * Cardiological and other diseases that threaten the use of anesthesia. * Pancreatitis (acute or exacerbation of chronic inflammation).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Locally advanced are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Locally advanced Pancreatic ductal adenocarcinoma (PDAC) Unresectable

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fondazione Policlinico Universitario A. Gemelli, IRCCS

    RECRUITING

    Roma, Italy

  • Guy's & St Thomas' and Kings College Hospitals

    RECRUITING

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.